MiSight: myopia control gains retained one year after treatment cessation
CooperVision has published seven-year findings from its MiSight 1 day clinical trial
CooperVision has published new seven-year findings from its ongoing clinical trial exploring the effectiveness of MiSight 1 day contact lenses in controlling myopia.
The latest results, which were shared at the American Academy of Ophthalmology annual meeting (November 3-6, Boston), revealed that 12 months after the end of treatment, myopia control gains were retained in trial participants – with no evidence of a rebound effect.
Previous research published by CooperVision has illustrated how MiSight contact lenses slowed the progression of myopia over a six-year period.
Abnormal axial length growth slowed by an average of approximately 50% across all tested ages (between eight and 17).
Following six-years of treatment, study participants were transitioned from MiSight contact lenses to a single vision contact lens to assess whether treatment gains would be maintained.
The researchers determined that following the cessation of myopia management, progression occurred at ‘age-normal’ levels.
Dr Nicola Logan, study investigator and professor of optometry and physiological optics at Aston University, shared: “It is personally as well as professionally fulfilling to know that the benefits of treatment are retained.”
MiSight contact lenses are approved by the US Food and Drug Administration to slow the progression of myopia in children aged between eight and 12 at the initiation of treatment.
In August, the contact lenses also received approval from the Chinese National Medical Products Administration as the first indicated product that may slow the progression of axial length.